Updates in the Treatment of Diffuse Large B-cell Lymphoma - Episode 1
Christopher Flowers, MD, discusses the long-term efficacy with tafasitamab-cxix in combination with lenalidomide in diffuse large B-cell lymphoma.
Christopher Flowers, MD, Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the long-term efficacy with tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) in diffuse large B-cell lymphoma (DLBCL).
Findings from the 3-year updated data of the phase 2 L-MIND trial (NCT02399085) demonstrated that at a median follow-up of at least 35 months, the median progression-free survival with tafasitamab/lenalidomide was 23.5 months for patients with relapsed/refractory DLBCL who received 1 prior treatment vs 7.6 months for patients who received 2 or more prior treatments, Flowers says. As such, there does appear to be a significant difference in efficacy based on number of prior treatments, Flowers adds.
The median overall survival was 45.7 months in patients with 1 prior treatment vs 15.5 months in patients with at least 2 prior treatments, Flowers says. Although the trial was not powered to compared patients based on prior number of treatments, the efficacy data indicate that patients who had 1 prior therapy derived higher rates of complete responses vs those who received 2 or more prior therapies, Flowers, explains.
In many clinical scenarios, the less patients are pretreated, they better they tend to do with a novel treatment, Flowers explains. However, the differences observed based on prior treatment were notable with tafasitamab/lenalidomide, Flowers concludes.